Introduction {#s1}
============

Co-infection with Hepatitis C (HCV) and HIV is common, and HIV accelerates hepatic disease progression due to HCV [@pone.0055373-Benhamou1]. As a result, HCV has become a leading cause of death of people living with HIV in Western settings [@pone.0055373-Rockstroh1]. Successful treatment of HCV can improve hepatic fibrosis, reduce incidence of hepatocellular carcinoma, reduce mortality [@pone.0055373-Singal1], [@pone.0055373-Limketkai1], and has the potential to reduce disease transmission [@pone.0055373-Durier1]. However, a number of factors contribute to the limited access to treatment for most of those infected globally: a long duration of therapy with a relatively complex system of treatment delivery, high drug costs, high toxicity of treatment and, perhaps most importantly, relatively poor success rates for HCV treatment in HIV/HCV co-infection.

A recent systematic review of clinical trials assessing HCV treatment outcomes in HIV co-infected patients reported that around 37% of patients achieve a sustained virological response (SVR) with pegylated interferon and ribavarin, with a lower success rate observed in patients infected with HCV genotypes 1 and 4 [@pone.0055373-Iorio1]. These outcomes are poorer than those seen in HIV negative patients [@pone.0055373-Ford1]. Although clinical trials are appropriate for determining drug efficacy, outcomes may differ under programmatic conditions where adherence to treatment, patient and provider motivation and available resources may be limited [@pone.0055373-Vandenbroucke1]. We conducted a systematic review to assess the outcomes of HCV treatment in HIV co-infected patients in programmatic settings.

Methods {#s2}
=======

Search Strategy and Study Selection {#s2a}
-----------------------------------

Our systematic review was conducted in accordance with the criteria of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses group [@pone.0055373-Liberati1]. Using a pre-defined protocol ([File S1](#pone.0055373.s001){ref-type="supplementary-material"}) Medline and EMBASE were systematically searched from inception to 05 May, 2012 using a compound search strategy. The initial title screen was conducted by one of us (AD) with full text articles reviewed in duplicate (AD, NF). The bibliographies of relevant articles were also hand searched for potentially relevant articles. Agreement on inclusion of final articles was made through consensus by the same reviewers. No language or geographical restriction was applied during the search, but only English language publications were included in the final review.

All cohort studies that reported treatment outcomes for in HIV-positive patients chronically infected with HCV and initiating HCV treatment for the first time were reviewed. Studies were excluded if they reported outcomes among patients with selected co-morbidities other than HIV, such as haemophilic or transplant patients, and if treatment outcomes involved acute HCV infection. Randomised trials were excluded in keeping with the aim of assessing outcomes in programmatic settings (defined as cohort reports in health care settings where there was no randomisation or control group comparison). In cases of potential duplication of studies, the largest report covering the longest time period was included and authors were contacted for clarification.

Patient and study characteristics were extracted in duplicate (AD, KS), with third party arbitration in case of disagreement (NF). The primary outcome was the proportion of patients achieving a SVR, calculated on an 'intent-to-treat' basis with all patients starting treatment contributing to the denominator. Secondary outcomes included the proportion of patients achieving a rapid virological response (RVR), defined as an undetectable (\<50 copies/mL) serum level of HCV RNA at week 4 of treatment; discontinuation of treatment due to adverse drug reactions; loss to care (default); and death.

Data Analysis {#s2b}
-------------

Point estimates and 95% confidence intervals (95% CI) were calculated for all primary and secondary outcomes. The variance of raw proportions was stabilised using a Freeman-Tukey type arcsine square-root transformation [@pone.0055373-Freeman1] and proportions were then pooled using a DerSimonian and Laird random effects model [@pone.0055373-DerSimonian1]. We calculated the τ^2^ statistic using DerSimonian and Laird's method of moments estimator [@pone.0055373-DerSimonian1] to assess between-study heterogeneity [@pone.0055373-Higgins1]. Sources of heterogeneity were explored through univariate subgroup analyses to assess the potential influence of baseline liver damage, genotype, type of HCV treatment and co-treatment with highly-active antiretroviral therapy (HAART). All analyses were conducted using Stata version 12 (StataCorp LP, College Station, Texas, USA), with a P-value ≤0.05 considered as significant.

Results {#s3}
=======

887 articles were screened, and 103 of these were reviewed in full ([figure 1](#pone-0055373-g001){ref-type="fig"}). After identification of further papers which did not meet the inclusion criteria (e.g. studies that included retreated patients or studies that did not report treatment outcomes in full), we retained 77 studies for detailed review. Over half of these studies (37) were from Spain, and after correspondence with authors, 37 studies were excluded as partial or complete duplicate cohorts [@pone.0055373-AguilarMarucco1]--[@pone.0055373-Zinkernagel1]. The final analysis included data on 5339 patients from 40 studies in 17 countries ([Table 1](#pone-0055373-t001){ref-type="table"}).

![Identification of studies for inclusion.](pone.0055373.g001){#pone-0055373-g001}
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###### Characteristics of included studies.

![](pone.0055373.t001){#pone-0055373-t001-1}

  Study                           Study Characteristics   Patient Characteristics                                                                                                                                                                                                                                                                                                                                        
  ------------------------------ ----------------------- ------------------------- ------ ---------------------------------- --------------------------------------------------------------- ---------------------- ------- ------------------------------------------------ -------------------------------------- -------------------------------------------- ------------------------------------------------------- --------------------------------------------------------------------------------
  Aguilar et al 2008               Prospective cohort              Italy             52        40 (37--42) Median (IQR)                                    NS                                 1/4∶55.8%; 2/3∶44.2%    NS              491 (411--620) Median (IQR)                            21.2%                                    PEG-IFN                                            WB RBV                                                            All 48 weeks
  Amorosa et al 2010              Retrospective cohort              USA             212        48 (43--52) Median (IQR)       139 IVDU; 22 MSM; 87 WSM; 11 cocaine; 8 transfusion; 15 other   1/4∶87.3%; 2/3∶13.6%   32.5%             487 (355--675) Mean (IQR)                              100%                                    PEG-IFN                                            WB RBV                                                            All 48 weeks
  Araujo et al 2011                Prospective cohort             Brazil             26        41 (32--56) Mean (range)                                    NS                                 1/4∶57.7%; 2/3∶42.3%   15.4%            570 (327--956) Mean (range)                            69.2%                                    PEG-IFN                                            WB RBV                                                            All 48 weeks
  Avidan et al 2009                Prospective cohort      USA Spain and Austria     32                   NS                                     14 IVDU; 18 MSM; 2 WSM                       1/4∶82.1%; 2/3∶17.9%   17.9%                         NS                                        84.4%                                    PEG-IFN                                            WB RBV                                                            All 48 weeks
  Berenguer et al 2011            Retrospective cohort             Spain            1701       41 (37--44) Median (IQR)                1382 IVDU; 75 excessive alcohol consumption            1/4∶62.9%; 2/3∶34.3%   38.2%            514 (390--720) Median (IQR)                            88.3%                                    PEG-IFN                                            WB RBV                                                                 NS
  Burbelo et al 2010               Prospective cohort               USA              29                   NS                                         13 IVDU; 19 MSM                          1/4∶82.8%; 2/3∶17.2%    NS                       All \<100                                       NS                                     PEG-IFN                                            WB RBV                                                            All 48 weeks
  Cesari et al 2009               Retrospective cohort             Italy             96        43 (41--46) Median (IQR)                                    NS                                   1/4∶50%; 2/3∶50%     17.7%            556 (422--722) Median (IQR)                            90.6%                                    PEG-IFN                                            WB RBV                                                            All 48 weeks
  Cooper et al 2010               Retrospective cohort            Canada             41                   NS                                               NS                                 1/4∶72.5%; 2/3∶27.5%    NS                 549 (±274); Mean (SD)                               82.9%                   'All formulations of IFN and RBV included'                            NS                                                                   NS
  Fleming et al 2005              Retrospective cohort              USA              21                   NS                                               NS                                 1/4∶61.9%; 2/3∶38.1%    NS                           NS                                          NS                                        NS                                                NS                                                                   NS
  Gonvers et al 2010               Prospective cohort           Switzerland          47                   NS                                             40 IVDU                              1/4∶48.9%; 2/3∶51.1%   43.5%                         NS                                        76.6%                                    PEG-IFN                                            WB RBV                                               Gen 1/4 = 48 weeks; Gen 2/3 = 24 weeks
  James et al 2012                Retrospective cohort            Canada             21               46.6 Mean                   9 IVDU; 15 MSM; 5 WSM; 9 blood products; 5 prisoners        1/4∶52.4%; 2/3∶47.6%   47.1%                      556 Mean                                     71.4%                                    PEG-IFN                                            WB RBV                           Gen 1 = 48 weeks; Gen 2/3 = 24, 32, 36 or 48 weeks according to viral response
  Karlstrom et al 2008             Prospective cohort             Sweden             13        51 (38--62) Mean (range)                                    NS                                       2/3∶100%          NS             430 (250--800) Median (range)                           76.9%                                    PEG-IFN                                            WB RBV                                                            All 24 weeks
  Kieran et al 2011               Retrospective cohort            Ireland           107       40 (23--58) Median (range)                 67 IVDUs; 20 blood products; 14 sexual               1/4∶51.4%; 2/3∶48.6%   13.2%                  5 patients \<200                                 71.9%                                    PEG-IFN                                            WB RBV                                                                 NS
  Laufer et al 2011                Prospective cohort            Argentina           20         40.5 (±4.8) Mean (SD)                                      NS                                       1/4∶100%          50%           All \>200; 521 (±218) Mean (SD)                           90%                                     PEG-IFN                                            WB RBV                                                            All 48 weeks
  Lerias de Almeida et al 2010    Retrospective cohort            Brazil             59           42 (±9) Mean (SD)                                        NS                                          NS            67.3%                      432 Mean                                       NS                                     PEG-IFN                                            WB RBV                                                            All 48 weeks
  Lopez-Cortes et al 2012          Prospective cohort              Spain             58       44 (27--57) Median (range)                                 47 IVDU                                    2/3∶100%         42.9%           395 (92--1500) Median (range)                           87.9%                                    PEG-IFN                                            FD RBV                                         Continue 20 weeks after undetectable serum RNA-HCV
  Macias et al 2010                Prospective cohort              Spain             97       42 (40--45) Median (range)                                 87 IVDU                               1/4∶68.0%; 2/3∶32%    78.5%                         NS                                        95.9%                                    PEG-IFN                                            WB RBV                                      Gen 1 or 4 = 48 or 72 weeks; Gen 2 or 3 = 24 or 48 weeks
  Marchetti et al 2012            Retrospective cohort             Italy             98        44 (41--46) Median (IQR)                           87 IVDU; 3 MSM; 8 WSM                       1/4∶45.9%; 2/3∶54.1%   74.5%           430 (321.5--567); Median (IQR)                           98%                                 PEG-IFN plus RBV                                       WB RBV                                              48 or 72 weeks, 'according to genotype'
  Maru et al 2008                 Retrospective cohort              USA              19                   NS                                          19 prisoners                            1/4∶78.9%; 2/3∶21.1%    NS              584 (490--696); Median (IQR)                            79%                                     PEG-IFN                                     Mix of WB and FD RBV                                                          NS
  Mehta et al 2006                Retrospective cohort              USA              29        39 (36--43) Median (IQR)                                  19 IVDU                              1/4∶89.7%; 2/3∶10.3%   52.9%        \<200 = 2; 200--350 = 15; \>350 = 12                       58.6%                                 STD or PEG-IFN                                   ± RBV (dosing NS)                                                           NS
  Michielsen et al 2009            Prospective cohort             Belgium            37       34 (17--60) Median (range)             15 IVDU; 7 blood products; 15 other or unknown           1/4∶59.5%; 2/3∶40.5%   55.9%          481 (222--1169); Median (range)                          64.9%                                    PEG-IFN                                            WB RBV                                                            All 52 weeks
  Mira et al 2009                  Prospective cohort              Spain            542                   NS                                            462 IVDU                                1/4∶65%; 2/3∶35%      68%    CD4≤250 = 39 patients; CD4\>250 = 503 patients                  82.7%                                    PEG-IFN                                            WB RBV                                         Gen 1 or 4 = 48 weeks; Gen 2 or 3 = 24 or 48 weeks
  Murray et al 2011               Retrospective cohort            Canada             64        44 (39--50) Median (IQR)                              33 IVDU; 27 MSM                          1/4∶51.5%; 2/3∶48.5%    52%             400 (270--510) Median (IQR)                            71.9%                                    PEG-IFN                                     Mix of WB and FD RBV                          Gen 1 = 48 weeks; Gen 2/3 = 24 weeks (with potential to continue)
  Nasti et al 2001                 Prospective cohort              Italy             17        36 (27--47) Mean (range)                                  17 IVDU                              1/4∶64.8%; 2/3∶35.2%    NS                  445 (144) Mean (SD)                                94.1%                                    STD-IFN                                            WB RBV                                                            All 24 weeks
  Neukam et al 2012                Prospective cohort        Spain and Germany      521        42 (39--46) Median (IQR)                                 391 IVDU                                1/4∶70%; 2/3∶30%     39.5%            483 (355--665) Median (IQR)                              --                                     PEG-IFN                                            WB RBV                               Gen 1 or 4 = 48 or 72 weeks; Gen 2 or 3 = 24 weeks (when RVR achieved)
  Nicot et al 2008                Retrospective cohort            France             35           41 (±8) Mean (SD)                                        NS                                   1/4∶60%; 2/3∶40%      NS                        444 Mean                                     68.6%                                    PEG-IFN                                            WB RBV                                                            All 48 weeks
  Nischalke et al 2010             Prospective cohort             Germany           109        45 (29--68) Mean (range)                                    NS                                          NS             NS              524 (216--1902) Mean (range)                             NS                                     PEG-IFN                             RBV 'according to current guidelines'                          24 or 48 weeks 'according to current guidelines'
  Poizot-Martin et al 2003         Prospective cohort             France             62        36 (34--40) Median (IQR)                             49 IVDU; 13 other                         1/4∶67.7%; 2/3∶32.3%   76.7%            494 (327--657) Median (IQR)                            88.7%                                 PEG or STD IFN                                        FD RBV                                                At least 24 weeks and up to 48 weeks
  Reiberger et al 2011            Retrospective cohort      Germany and Austria     416           43 (±8) Mean (SD)              201 IVDU; 83 MSM; 20 WSM; 21 blood products; 91 unknown      1/4∶71.8%; 2/3∶28.2%   35.1%                530 (±242) Mean (SD)                               56.9%                                    PEG-IFN                         FD RBV (adjusted for genotype but not weight)                                        All 48 weeks
  Reiberger et al 2008            Retrospective cohort            Austria            30           37 (±8) Mean (SD)                                        NS                                 1/4∶73.3%; 2/3∶26.7%    50%                 568 (±276) Mean (SD)                                60%                                     PEG-IFN                         FD RBV (adjusted for genotype but not weight)                      All 48 weeks (with option to extend to 72 weeks)
  Righi et al 2008                Retrospective cohort             Italy             43          41 (±6.7) Mean (SD)                                 32 IVDU; 4 WSM                           1/4∶48.8%; 2/3∶51.2%    40%     \>500 in 22/43 patients; \<350 in 6 patients                   37.2%                                    PEG-IFN                                            WB RBV                                              Gen 1 or 4 = 48 weeks; Gen 3a = 24 weeks
  Sacchi et al 2011                Prospective cohort              Italy             19                   NS                                               NS                                 1/4∶42.1%; 2/3∶57.9%   18.2%           458 (122--842); Median (range)           HAART suspended during HCV treatment                    PEG-IFN                                            WB RBV                                                            All 48 weeks
  Santin et al 2006                Prospective cohort              Spain             60           38.1±5.3 Mean (SD)                                50 IVDU; 8 sexual                         1/4∶68.3%; 2/3∶31.7%    NS                  645 (±351) Mean (SD)                                90%                                     PEG-IFN                                            WB RBV                                            Gen 1 or 4 = 48 weeks; Gen 2 or 3 = 24 weeks
  Sarmento-Castro et al 2007       Prospective cohort            Portugal            53               32.6 Mean                                     45 IVDU; 8 sexual                         1/4∶52.8%; 2/3∶47.2%   12.5%                      585 Mean                                     69.8%                                    PEG-IFN                                            WB RBV                                            Gen 1 or 4 = 48 weeks; Gen 2 or 3 = 24 weeks
  Taylor et al 2011                Prospective cohort               USA              11        46 (37--61) Mean (range)              All patients were recovering IVDU on methadone                 1/4∶100%         54.5%            498 (210--868) Mean (range)                            90.9%                                    PEG-IFN                                            WB RBV                                                            All 48 weeks
  Thein et al 2007                 Prospective cohort            Australia           15         38.9 (±7.8) Mean (SD)                                      NS                                   1/4∶40%; 2/3∶60%     21.4%             363 (328--612); Mean (IQR)                            33.3%                                    PEG-IFN                                            WB RBV                                  Gen 1 = 48 weeks; Gen 2 or 3 = 24 weeks (with option to extend)
  Van den Eynde et al 2010        Retrospective cohort             Spain            278    39.8 (36.4--42.8) Median (range)                             236 IVDU                                    1/4∶100%         62.3%                   495 (357--692)                                  88.8%                                    PEG-IFN                                     Mix of WB and FD RBV                                                     All 48 weeks
  Wagner et al 2011               Retrospective cohort              USA              72              48\. 1 Mean                                           NS                                 1/4∶70.8%; 2/3∶29.2%    NS                 534 (±234); Mean (SD)                               91.7%                                    PEG-IFN                                            RBV NS                                                       24--32, 48 or 72 weeks
  Yotsuyanagi et al 2009          Retrospective cohort             Japan             60                   NS                                 High proportion blood products                    1/4∶36.7%; 2/3∶30%     NS                           NS                                          NS                                     STD-IFN                     RBV given in 35 patients, not in 25 (dose not stated)               Gen 1 or 4 or other = 48 weeks; Gen 2 or 3 = 24 weeks
  Zinkernagel et al 2006          Retrospective cohort          Switzerland         160        41 (37--44) Median (IQR)                122 IVDU; 21 WSM; 11 MSM; 6 blood products             1/4∶44.1%; 2/3∶54.4%   46.6%           490 (334--662.5) Median (IQR)                           75.6%                                    PEG-IFN                      FD RBV (dose adjusted for phenotype but not weight)                                          NS

FD RBV, fixed-dose ribavarin; IQR, interquartile range; IVDU, intravenous drug use; MSM, men who have sex with men; NS, not stated; PEG-IFN, pegylated interferon; SD, standard deviation; STD-IFN, standard interferon; WB RBV, weight-based ribavarin; WSM, women who have sex with men.

The proportion of patients with liver damage at baseline ranged from 12.5% to 74%. The majority of studies (36) included a mix of HCV genotypes. Three studies (from Argentina, Spain and the USA) were exclusively comprised of patients infected with genotypes 1 and 4 and two studies (from Sweden and Spain) were exclusively comprised of patients infected with genotypes 2 and 3.

HCV treatment comprised pegylated interferon and weight-based ribavarin in most cases, and the majority of patients (84%) received concomitant antiretroviral therapy. Liver damage was assessed by biopsy in over half (25) of studies. One study used fibroscan to assess liver damage, and 3 studies used a combination of the 2 techniques. Nine studies did not assess liver damage while the remainder of the studies (3) did not state the method used.

The proportion of patients achieving SVR ranged from 13.8% (2.2--32.9%) to 71.9% (48.2--90.5%), with a pooled proportion of 38% (34.7--42.3%) (τ^2^ 0.037). Three studies were 'adherent cohorts' comprising only patients who completed treatment; removing these studies from the analysis did not affect the overall result. The result was also unaffected by a sensitivity analysis that included all studies from Spain regardless of potential overlap (pooled SVR 39%). The most important determinant of treatment success was HCV genotype, with significantly poorer outcomes for patients infected with HCV genotypes 1 or 4 (3371 patients, pooled SVR 24.5% (95%CI 20.4--28.6%), compared to genotypes 2 or 3 (1878 patients, pooled SVR 59.8% (95%CI 47.9--71.7%). Cohorts in which more than 50% of patients had advanced liver fibrosis at baseline (Metavir F3 or F4 or equivalent) [@pone.0055373-Bedossa1] had poorer outcomes compared to cohorts where less than 50% of patients had advanced liver disease (42.8%\[36.7--49%\] versus 34.4%\[27--41.8%\]). Subgroup analyses are summarized in [Figure 2](#pone-0055373-g002){ref-type="fig"}.

![Sustained virological response (SVR) in patients co-infected with HCV and HIV by disease, patient and treatment covariates.](pone.0055373.g002){#pone-0055373-g002}

Rapid virological response, reported by 5 studies, was achieved by 30.9% of patients (11.2--50.8%). The pooled proportion of patients who discontinued treatment due to drug toxicities (reported by 33 studies) was low, at 4.3% (3.3--5.3%). Defaulting from treatment, reported by 33 studies, was also low (5.1%, 3.5--6.6%), as was on-treatment mortality, (35 studies, 0.1% (0--0.2%)).

Discussion {#s4}
==========

Currently, access to effective HCV treatment is limited, particularly for those with HCV/HIV co-infection in resource-limited settings. This is reflected in this study by the paucity of data reoprted from such settings. Among the 40 studies assessed, only three were from resource-limited settings (two from Brazil and one from Argentina), and no reports were found from African countries, including Egypt where the burden of HCV is the highest in the world, or sub-Saharan Africa where the burden of HIV is the highest in the world. Limited access to treatment in resource-limited settings is in part due to the high cost of treatment, a perception of poorer outcomes of HCV treatment in HIV co-infected patients, and the potential difficulties associated with adherence and drug interactions under programmatic conditions.

Concern has recently been expressed that the relatively high efficacy of hepatitis treatment reported in clinical trials is not attained in subsequent effectiveness studies carried out in the general population under programmatic conditions [@pone.0055373-Mitchell1]. In comparison to routine programmes, patients in clinical trials tend to be more adherent to treatment, and will usually receive treatment free of charge provided by highly motivated clinical staff working in optimal clinical settings [@pone.0055373-Scaglione1]. Nevertheless, this review found that programmatic outcomes were in very close alignment to a systematic review of outcomes in clinical trials, which found that HCV treatment responses in HIV co-infected patients is lower than those observed in HIV-negative individuals [@pone.0055373-Gluud1]. Nevertheless, for HIV-positive patients infected with HCV genotypes 2 or 3, treatment outcomes are very similar (SVR 60%) to those reported for HIV-negative HCV patients infected with the same genotypes in programme settings (SVR 59%) [@pone.0055373-Ford1].

Treatment completion was generally high, with few patients discontinuing treatment due to adverse events or defaulting from care. The use of HAART was not associated with better outcomes, which is consistent with other studies [@pone.0055373-Chung1], [@pone.0055373-Medrano1].

We used a broad search strategy that allowed the inclusion of a large number of studies. We restricted studies to observational cohorts so that the expected outcomes would better reflect those observed in programmatic settings, but this can result in confounding. Concomitant use of medications, unreported mental or physical problems, or ancillary health service support could all influence treatment outcomes, but these factors were not reported and so could not be assessed. We attempted to use multivariate meta-regression to explore the potential influence of patient and programme level variables to explain differences in results between studies. However, this was restricted by inconsistent reporting between studies, so our exploration of associations was limited to univariate subgroup comparisons. In addition, bias may result from studies that pre-selected patients on the basis of characteristics that may influence treatment success, or excluded patients with risk factors for poor adherence. Furthermore, the final analysis only included studies published in English, which may lead to publication bias. Only five studies, however, were excluded on the basis of language and their influence would likely be small. Nevertheless, this review should be taken as an indication of outcomes and not as an exhaustive summary.

The treatment of HCV infection is likely to evolve rapidly as a result of a dynamic drug pipeline. For example, the first HCV protease inhibitors have just been recently approved. In the short to medium-term, however, the majority of HIV-positive patients living in resource-limited settings are unlikely to benefit from these newer treatments, just as they continue to lack access to many of the newer antiretroviral drugs for HIV that have been marketed in the West for many years. The results of this systematic review support the current practice of treatment in well resourced settings, whilst serving as a reminder for the need for better treatments. This review also highlights the need to encourage treatment of HCV/HIV co-infected patients in resource-limited settings to start programmes in parallel to efforts aimed at reducing costs of current treatment and gaining access to newer, interferon free regimens so that new advances in treatment can be rapidly accessed by all those that need them.
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